Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

CARVYKTI 100000000 CELLS — DIN 02535270

CILTACABTAGENE AUTOLEUCEL : 100000000 CELLS · JANSSEN INC · SUSPENSION · wholesale supply in Canada

Health Canada status: APPROVED

What is CARVYKTI?

CARVYKTI 100000000 CELLS contains CILTACABTAGENE AUTOLEUCEL : 100000000 CELLS. It is listed in the Health Canada Drug Product Database under DIN 02535270, held by JANSSEN INC, supplied as SUSPENSION for INTRAVENOUS administration. Health Canada currently lists it as approved, status dated 09-Feb-2023. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A). This DIN is not currently being marketed in Canada, so it is sourced to order where a compliant route exists rather than held in stock.

How much does Ciltacabtagene Autoleucel cost around the world?

Ciltacabtagene Autoleucel is listed on 3 of the national price registers Nexara ingests. Each country publishes on a different basis, so figures are not comparable with one another — or with a Canadian wholesale price.

What a market publishes matters more than the number it publishes. Greece publishes a producer price (ex-factory); Italy publishes a ex-factory (classe H); Saudi Arabia publishes a public. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.

MarketPrice basis published thereBrandsPacks listed
Greeceproducer price (ex-factory)11
Italyex-factory (classe H)11
Saudi Arabiapublic11

3 pack listings across 3 brand entries and 3 price bases, refreshed 03 Sep 2026. Ranges span every Ciltacabtagene Autoleucel pack in that market, so a high figure is usually a larger pack rather than the same product.

Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.

Ask Nexara for a landed Canadian price

How is it supplied and stored?

Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.

Strength on the label100000000 CELLS
Dosage formSUSPENSION
RouteINTRAVENOUS

Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.

Substance and classification

Active substanceCiltacabtagene Autoleucel
ATC codeL01XL05
AHFS class28:12.92
Biosimilar biologicNo

Confirm the pack and get a price

Health Canada record and identifiers

The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.

DIN (8-digit, as used in ordering)02535270
DIN (unpadded, as printed on some documents)2535270
Brand nameCARVYKTI
Generic / active ingredientCILTACABTAGENE AUTOLEUCEL : 100000000 CELLS
Market authorization holderJANSSEN INC
Health Canada schedulePrescription
ATC codeL01XL05
ATC anatomical main groupL — Antineoplastic and immunomodulating agents
ATC therapeutic subgroupL01XL
Current statusAPPROVED
Status date09-Feb-2023
Original market date2024-03-07 00:00:00
Status sourceLive Health Canada DPD sync

Verify on the primary sources

Health Canada DPD record Approved product monograph (PDF)

What can be used instead?

Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.

2 · Same class — other molecules in ATC L01XL

MoleculeCanadian brandsDINsMarketedSourceable
Brexucabtagene AutoleucelTECARTUS22Yes
Lisocabtagene MaraleucelBREYANZI11Yes
TisagenlecleucelKYMRIAH11Yes
Axicabtagene CiloleucelYESCARTA11Yes
Idecabtagene VicleucelABECMA10Not in Canada
Ciltacabtagene AutoleucelCARVYKTI10Not in Canada
LifileucelAMTAGVI10Not in Canada

A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.

3 · Adjacent classes in ATC L01X

ATC subgroupMoleculesDINsMarketed
L01XXAflibercept · Altretamine · Amsacrine · Anagrelide · Arsenic Trioxide · +13 more4823
L01XGBortezomib · Carfilzomib · Ixazomib3018
L01XACarboplatin · Cisplatin · Oxaliplatin4512
L01XKNiraparib · Niraparib And Abiraterone · Olaparib · Talazoparib127
L01XJGlasdegib · Sonidegib · Vismodegib44
L01XDAminolevulinic Acid · Methyl Aminolevulinate · Porfimer Sodium53
L01XHRomidepsin · Vorinostat22
L01XFTretinoin22

Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.

How can I get it?

This product is approved by Health Canada but not yet marketed in Canada, so there is no Canadian supply to draw on today. Nexara can tell you whether it has been launched, and can look at supply from other markets where a Canadian pack is not required or where importation is permitted.

Ask about availability of CARVYKTI

Ordering questions

Who can buy this from Nexara?

Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.

Is there a minimum order?

Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.

What is the lead time?

Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.

Why is there no price on this page?

Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.

Can Nexara supply this for a clinical trial?

Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.

Sources and disclaimer

Product data sourced from the Health Canada Drug Product Database and the approved product monograph (PDF). Health Canada status reconciled against the live DPD sync. Last reviewed 11 Sep 2026.

Nothing on this page is medical advice. Nexara Health is a licensed wholesale distributor and supplies licensed entities only; consumer orders are routed to a partner pharmacy. Alternatives tables describe supply, not clinical equivalence.

Health Canada Drug Product Database (DPD), DIN 02535270. Last reviewed 2026-09-11. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.